(By Umesh Ishalkar) The use of the makers of monoclonal antibodies in Covid patients has encouraged the country to frame the protocol on the use of cocktail drugs that require Rs 60,000 to Rs 70,000 per dose.
According to the design of the guidelines, every doctor or hospital who is willing to prescribe it must first get rid of it is an Omicron case using a test failed to target genomes or through genome sequencing.
Roche antibody cocktails (containing Casoliivimab and IMdevimab), which are marketed by Cipla in India, does not maintain neutralizing activity against omicrons with the acceptance of producers.
Despite Roche’s statement, it was prescribed and driven indiscriminately by all the quarters to get a profit, a senior official stated to TOI.
“The hospital has arranged the OPD bed only to manage this drug, but because it is expensive, many are hospitalized for a day so that their medical insurance includes it,” the official added.
Violence, antibody cocktails are not the only drugs that are misused in covid treatment in the state.
Members of the National Covid task task said they were worried about Molnupiravir, anti-virus drugs intended for covid, and a widely determined azithromycin.
The protocol proposed in monoclonal antibodies has said Covid patients above 12, which is at high risk of severe disease progress, can receive drugs regardless of vaccination status when they show mild to moderate symptoms and do not require oxygen.
Elderly, obesity, people with chronic kidney disease, heart disease, immuno peeler disorders, among others, have been registered as several categories with severe risk affected risk.
Individuals who are not expected to install adequate immune responses to vaccination can also be candidates.
Some doctors said they ruled out omicrons before starting treatment impractically because the test of the target of genes was not available at any hospital and the Genom sequencing report took between 5-7 days.
State officials retaliated that every hospital that manages monoclonal antibodies can invest in a target gene target kit that can provide results in three hours.
Dr.
Vasant Nagvekar, Infectious Disease Consultants and members of the Covid Task Force, said the antibody cocktail is certainly not for each patient.
But distinguishing between Delta and Omicron based on clinical symptoms is difficult.
“Some of the markers we go through are CT scan abnormalities, prolonged fever coming and going, longer incubation period – all of this can be a sign of tentative infection by Delta,” he said.
Nagvestar added that the ICU saw more entrance tickets and it was important not to miss the delta under the Omicron cover.
Experts are also worried about prescribed oral drugs.
“Molnupiravir is not recommended for the management of mild diseases …
In Molnupiravir studies, simple benefits are only seen among patients who are not divirious with obesity,” said Sanjay Pujari’s infectious disease, a member of the National Task Force.
“Similarly, antibacterial, including azithromycin, is also being adjusted to mild covid patients,” he said.
Dr.
Chandrashekhar T, Director (Critical Care), Fortis Hiranandani, Vashi said many mild cases were purely viruses and can be treated symptomly.
“Molnupiravir and azithromycin have not been included in the ICMR guidelines
Maharashtra plans the norm to curb the use of rampant monoclonal antibodies
